Omega Therapeutics, Inc.
OMGADelisted Mar 20, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001850838
Omega Therapeutics, Inc. was delisted on Mar 20, 2025; its insiders filed their last Form 4 on Dec 5, 2024; 53 institutions reported holding it in 13F filings for Q4 2024, worth $35.3M in total; no superinvestor held it.
Q2 2022 vs. Q1 2022
How the institutions holding Omega Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 52 | 1 | 47 | −4 |
| Shares | 43.5M | 2.98K | 42.5M | −1.06M (−2.4%) |
| Value | $271.7M | $19.0K | $161.4M | −$110.3M (−40.6%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Omega Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Laurion Capital Management LP | 432,700 | $1.64M | 0.07% |
| State of Michigan Retirement System | 314,117 | $1.19M | 0.01% |
| Oasis Management Co Ltd. | 160,000 | $608.0K | 0.11% |
| Renaissance Technologies LLC | 95,663 | $364.0K | 0.00% |
| RBF Capital, LLC | 77,307 | $294.0K | 0.02% |
| Rafferty Asset Management, LLC | 31,706 | $120.0K | 0.00% |
| Citadel Advisors LLC | 25,271 | $96.0K | 0.00% |
| Occudo Quantitative Strategies LP | 18,323 | $70.0K | 0.01% |
| Qube Research & Technologies Ltd | 13,619 | $52.0K | 0.00% |
| Schonfeld Strategic Advisors LLC | 13,600 | $51.0K | 0.00% |
| LPL Financial LLC | 10,932 | $42.0K | 0.00% |
| Wade G W & Inc | 10,000 | $38.0K | 0.00% |
| Cannell Capital LLC | 2,738 | $10.0K | 0.00% |
| Parallel Advisors, LLC | 296 | $1.00K | 0.00% |
| Credit Suisse AG | 12 | $0 | 0.00% |
Sold out (19)
Institutions that held Omega Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Octagon Capital Advisors LP | 176,470 | $1.10M |
| Monashee Investment Management LLC | 123,614 | $771.0K |
| Victory Capital Management Inc | 102,330 | $639.0K |
| Bank of New York Mellon Corp | 55,277 | $344.0K |
| Charles Schwab Investment Management Inc | 52,799 | $330.0K |
| Nuveen Asset Management, LLC | 31,685 | $219.0K |
| Rhumbline Advisers | 15,329 | $96.0K |
| Allspring Global Investments Holdings, LLC | 14,030 | $87.0K |
| Logos Global Management LP | 12,986 | $81.0K |
| Deutsche Bank AG | 12,337 | $77.0K |
| American International Group, Inc. | 11,058 | $69.0K |
| Two Sigma Investments, LP | 10,607 | $66.0K |
| California State Teachers Retirement System | 9,475 | $59.0K |
| Amalgamated Bank | 2,981 | $19.0K |
| Legal & General Group Plc | 2,156 | $13.0K |
| Ameritas Investment Partners, Inc. | 1,717 | $11.0K |
| STRS Ohio | 1,700 | $10.0K |
| Point72 Hong Kong Ltd | 602 | $4.00K |
| UBS Group AG | 297 | $2.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Omega Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 2,981 | $19.0K |